Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 4
2004 3
2005 3
2006 6
2007 1
2008 3
2009 4
2010 2
2011 10
2012 9
2013 10
2014 9
2015 14
2016 14
2017 10
2018 13
2019 7
2020 9
2021 12
2022 12
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAESTRO-NASH Investigators. Harrison SA, et al. N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000. N Engl J Med. 2024. PMID: 38324483 Clinical Trial.
Busting the myth of methotrexate chronic hepatotoxicity.
Di Martino V, Verhoeven DW, Verhoeven F, Aubin F, Avouac J, Vuitton L, Lioté F, Thévenot T, Wendling D. Di Martino V, et al. Nat Rev Rheumatol. 2023 Feb;19(2):96-110. doi: 10.1038/s41584-022-00883-4. Epub 2022 Dec 23. Nat Rev Rheumatol. 2023. PMID: 36564450 Review.
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. Francque SM, et al. N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205. N Engl J Med. 2021. PMID: 34670042 Clinical Trial.
Diagnosis and management of hepatic encephalopathy: The French recommendations.
Thabut D, Bouzbib C, Meunier L, Haas M, Weiss N, Louvet A, Imbert-Bismut F, Mochel F, Nadjar Y, Santiago A, Thevenot T, Duhalde V, Oberti F, Francoz C, Coilly A, Hilleret MN, Lebray P, Liou-Schischmanoff A, Barbier L, Duvoux C, Pageaux GP, Bismuth M, Galanaud D, Broucker T, Cadranel JF, Leroy V, Di Martino V, Larrey D, Camus C, Scatton O, De Ledinghen V, Mallat A, Rudler M, Bureau C; Association Française pour l'Etude du Foie (AFEF) group of experts of HE recommendations. Thabut D, et al. Among authors: di martino v. Liver Int. 2023 Apr;43(4):750-762. doi: 10.1111/liv.15510. Epub 2023 Jan 24. Liver Int. 2023. PMID: 36625084 Review.
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, Hammel P, Rosmorduc O, Stouvenot M, Allaire M, Bouattour M, Regnault H, Fratte S, Raymond E, Soularue E, Husson-Wetzel S, Di Martino V, Muller A, Clairet AL, Fagnoni-Legat C, Adotevi O, Meurisse A, Vernerey D, Borg C. Vienot A, et al. Among authors: di martino v. BMC Cancer. 2023 Jul 29;23(1):710. doi: 10.1186/s12885-023-11065-0. BMC Cancer. 2023. PMID: 37516867 Free PMC article. Clinical Trial.
New prognostic markers in liver cirrhosis.
Di Martino V, Weil D, Cervoni JP, Thevenot T. Di Martino V, et al. World J Hepatol. 2015 May 28;7(9):1244-50. doi: 10.4254/wjh.v7.i9.1244. World J Hepatol. 2015. PMID: 26019739 Free PMC article. Review.
Alfapump® implantable device in management of refractory ascites: An update.
Weil-Verhoeven D, Di Martino V, Stirnimann G, Cervoni JP, Nguyen-Khac E, Thévenot T. Weil-Verhoeven D, et al. Among authors: di martino v. World J Hepatol. 2022 Jul 27;14(7):1344-1356. doi: 10.4254/wjh.v14.i7.1344. World J Hepatol. 2022. PMID: 36158913 Free PMC article. Review.
153 results